13 December 2016 - Canadians living with non-Hodgkin's lymphoma, one of the most commonly diagnosed blood cancers in Canada, now have a new option that may help them minimise time spent in the chemotherapy suite. 

Health Canada has approved the subcutaneous formulation of Rituxan (rituximab) in combination with chemotherapy agents for the treatment of patients with low-grade CD20 antigen positive B-cell non-Hodgkin's lymphoma, who have not received prior treatment or who are no longer responding to their current treatment or where the lymphoma has returned despite previous treatment.

Read Canada Newswire article